These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME). McCluskey JD; Kaufman PL; Wynne K; Lewis G Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396 [No Abstract] [Full Text] [Related]
4. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Holden SE; Kapik B; Beiderbeck AB; Currie CJ Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759 [No Abstract] [Full Text] [Related]
5. The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema. Singh P; Chedid A; Deuchler SK; Kohnen T; Müller M; Koch FH Int Med Case Rep J; 2018; 11():265-269. PubMed ID: 30410411 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months. Moll-Udina A; Hernanz I; Sainz-de-la-Maza M; Pelegrín L; Coelho-Borges AI; Pazos M; Adán A; Llorenç V Int Ophthalmol; 2023 Nov; 43(11):4181-4195. PubMed ID: 37698661 [TBL] [Abstract][Full Text] [Related]
8. Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine-Gass Syndrome. Marques JH; Abreu AC; Silva N; Meireles A; Pessoa B; Melo Beirão J Int Med Case Rep J; 2021; 14():127-132. PubMed ID: 33664598 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy. Lima-Fontes M; Leuzinger-Dias M; Barros-Pereira R; Fernandes V; Falcão M; Falcão-Reis F; Rocha-Sousa A; Alves-Faria P Ophthalmol Ther; 2023 Feb; 12(1):377-388. PubMed ID: 36417092 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Currie CJ; Holden SE; Berni E; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal fluocinolone acetonide 0.19 mg (Iluvien®) for the treatment of uveitic macular edema: 2-year follow-up of 20 patients. Studsgaard A; Clemmensen KØ; Nielsen MS Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1633-1639. PubMed ID: 34851465 [TBL] [Abstract][Full Text] [Related]
12. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Schmit-Eilenberger VK Clin Ophthalmol; 2015; 9():801-11. PubMed ID: 25999689 [TBL] [Abstract][Full Text] [Related]
13. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051 [TBL] [Abstract][Full Text] [Related]
14. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758 [TBL] [Abstract][Full Text] [Related]
16. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema. Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148 [TBL] [Abstract][Full Text] [Related]
17. Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up. Elaraoud I; Quhill H; Quhill F Ophthalmol Ther; 2016 Jun; 5(1):105-9. PubMed ID: 27116231 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of 0.19-mg Fluocinolone Acetonide Implant in Postoperative Cystoid Macular Edema after Pars Plana Vitrectomy: the ILUCYD study. Motloch K; Soler V; Delyfer MN; Vasseur V; Wolff B; Issa M; Dot C; Massé H; Weber M; Comet A; Hitzl W; Matonti F; Creuzot-Garcher C; Tadayoni R; Kodjikian L; Couturier A Ophthalmol Retina; 2024 Jul; ():. PubMed ID: 39004282 [TBL] [Abstract][Full Text] [Related]